Merck
CN
  • α-Cyclodextrin dimer complexes of dopamine and levodopa derivatives to assess drug delivery to the central nervous system: ADME and molecular docking studies.

α-Cyclodextrin dimer complexes of dopamine and levodopa derivatives to assess drug delivery to the central nervous system: ADME and molecular docking studies.

International journal of nanomedicine (2012-07-20)
Sergey Shityakov, Jens Broscheit, Carola Förster
ABSTRACT

This paper attempts to predict and emphasize molecular interactions of dopamine, levodopa, and their derivatives (Dopimid compounds) containing 2-phenyl-imidazopyridine moiety with the α-cyclodextrin dimer in order to assess and improve drug delivery to the central nervous system. The molecular docking method is used to determine the energetic profiles, hydrogen bond formation, and hydrophobic effect of 14 host-guest complexes. The results show that the "chemical branching" represented by additional ethyl-acetate residue is energetically unfavorable and promotes a conformational shift due to the high root mean square deviation levels. This phenomenon is characterized by a low number of H-bonds and a significant decrease of the host-guest hydrophobic potential surface. Finally, the overall docking procedure presents a powerful rationale for screening and analyzing various sets of promising drug-like chemical compounds in the fields of supramolecular chemistry, molecular sensing, synthetic receptors, and nanobiotechnology.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
α-Cyclodextrin, produced by Wacker Chemie AG, Burghausen, Germany, ≥99.0% (HPLC)
Sigma-Aldrich
α-Cyclodextrin, ≥98%
Sigma-Aldrich
α-Cyclodextrin, powder, BioReagent, suitable for cell culture, ≥98%
Sigma-Aldrich
α-Cyclodextrin, purum, ≥98.0% (HPLC)
Sigma-Aldrich
α-Cyclodextrin, Produced by Wacker Chemie AG, Burghausen, Germany, Life Science, 98.0-101.0% cyclodextrin basis (HPLC)